Collagenase Clostridium Histolyticum injection therapies
US11253575B2 · kind B2 · utility
0Cited by
0References
15Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Oct 8, 2020 |
| Grant date | Feb 22, 2022 |
| Priority date | — |
| Expiry date | Oct 8, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P13/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Collagenase Clostridium histolyticum (EN3835) is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions. EN3835 targets the collagenase structural matrix at the site of injection and does not require systemic exposure. Embodiments include methods of lysing subdermal collagen to treat various conditions such as benign prostatic hyperplasia, tracheal stenosis, subglottic stenosis and scleroderma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.